Press release
Intrahepatic Cholangiocarcinoma Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, TriSalus Life Sciences, Jiangsu HengRui
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Intrahepatic Cholangiocarcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market.
Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report: https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. Intrahepatic Cholangiocarcinoma Key players such as - Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment
• Intrahepatic Cholangiocarcinoma Emerging therapies such as - XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.
• In January 2024, Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company specializing in advanced personalized MRD technology (Haystack MRDTM), has partnered with TriSalus Life Sciences for a research collaboration. This initiative aims to assess therapeutic responses and gather molecular insights during the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. SD-101 is administered through hepatic arterial infusion or pancreatic retrograde venous infusion in Phase 1 and 1b trials using TriSalus' proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) system, designed to address intratumoral pressure challenges in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic cholangiocarcinoma (ICC) is a rare and aggressive form of cancer that originates in the bile ducts within the liver. These bile ducts are responsible for carrying bile, a digestive fluid, from the liver to the small intestine. ICC typically develops when abnormal cells in the bile ducts begin to grow uncontrollably, forming a tumor. The exact cause of ICC is not always clear, but risk factors include liver diseases like cirrhosis, chronic hepatitis B or C infections, and certain genetic conditions. Symptoms of ICC may include jaundice, abdominal pain, weight loss, and fatigue. The condition is often diagnosed through imaging tests, biopsy, and blood tests. Treatment options for ICC include surgery, chemotherapy, and targeted therapies, but the prognosis is generally poor, particularly in advanced stages.
Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Route of Administration
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment
• Intrahepatic Cholangiocarcinoma Assessment by Product Type
• Intrahepatic Cholangiocarcinoma By Stage and Product Type
• Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
• Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
• Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
• Intrahepatic Cholangiocarcinoma by Stage and Molecule Type
DelveInsight's Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Intrahepatic Cholangiocarcinoma Therapeutics Market include:
Key companies developing therapies for the Intrahepatic Cholangiocarcinoma are - Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology, QED Therapeutics, Janssen Pharmaceutical, Taiho Oncology, RedHill Biopharma, GlaxoSmithKline, Merck, Eisai, Taiho Pharmaceutical, Sorrento Therapeutics, Yuhan Corporation, Hutchison Medipharma, Jiangsu HengRui Medicine, AstraZeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array BioPharma, and others
Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Intrahepatic Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:
• XmAb®22841: Xencor, Inc.
• RLY-4008: Relay Therapeutics
• KIN-3248: Kinnate Biopharma
• FT-2102: Forma Therapeutics, Inc.
• SD 101: TriSalus Life Sciences
• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
• VG161: Virogin Biotech Ltd
• Derazantinib: Basilea Pharmaceuticals
Intrahepatic Cholangiocarcinoma Pipeline Analysis:
The Intrahepatic Cholangiocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Intrahepatic Cholangiocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
• Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Intrahepatic Cholangiocarcinoma Pipeline Market Drivers
• Rising incidence of Cholangiocarcinoma. ICC makes up 8-10% of all Cholangiocarcinoma
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma Pipeline Market Barriers
• Poor prognosis and diagnosis of the disease
• Difficulty in developing novel therapies. Drugs may lose effectiveness after several months as the tumor may become resistant to the medication.
Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Intrahepatic Cholangiocarcinoma Companies: Xencor, Inc., Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, Inc., TriSalus Life Sciences, Jiangsu HengRui Medicine Co., Ltd., Virogin Biotech Ltd., Basilea Pharmaceuticals, and others
• Key Intrahepatic Cholangiocarcinoma Therapies: XmAb®22841, RLY-4008, KIN-3248, FT-2102, SD 101, Camrelizumab, VG161, Derazantinib, and others
• Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
• Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers
Request for Sample PDF Report for Intrahepatic Cholangiocarcinoma Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Intrahepatic Cholangiocarcinoma Report Introduction
2 Intrahepatic Cholangiocarcinoma Executive Summary
3 Intrahepatic Cholangiocarcinoma Overview
4 Intrahepatic Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment
5 Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
6 Intrahepatic Cholangiocarcinoma Late Stage Products (Phase II/III)
7 Intrahepatic Cholangiocarcinoma Mid Stage Products (Phase II)
8 Intrahepatic Cholangiocarcinoma Early Stage Products (Phase I)
9 Intrahepatic Cholangiocarcinoma Preclinical Stage Products
10 Intrahepatic Cholangiocarcinoma Therapeutics Assessment
11 Intrahepatic Cholangiocarcinoma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Intrahepatic Cholangiocarcinoma Key Companies
14 Intrahepatic Cholangiocarcinoma Key Products
15 Intrahepatic Cholangiocarcinoma Unmet Needs
16 Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
17 Intrahepatic Cholangiocarcinoma Future Perspectives and Conclusion
18 Intrahepatic Cholangiocarcinoma Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Related Reports:
Intrahepatic Cholangiocarcinoma Market https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Intrahepatic Cholangiocarcinoma-Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Intrahepatic Cholangiocarcinoma Epidemiology https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Intrahepatic Cholangiocarcinoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intrahepatic Cholangiocarcinoma Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics, TriSalus Life Sciences, Jiangsu HengRui here
News-ID: 4014181 • Views: …
More Releases from DelveInsight Business Research
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities i …
DelveInsight, a leading business consulting and market intelligence firm in healthcare, announces the release of its latest Competitive Landscape Assessment Case Study, showcasing opportunities in the dissolvable microneedle technology (dMTS) space. This in-depth analysis highlights how strategic evaluations and tailored solutions can enable global healthcare organizations to expand product offerings, secure intellectual property, and strengthen their competitive positions in the rapidly growing drug delivery market.
Gain firsthand access to a complimentary…
Competitive Intelligence in the Hematology Domain: Driving Strategic Success thr …
DelveInsight, a leader in healthcare consulting and competitive intelligence, has recently showcased its success in a long-term engagement for competitive intelligence support within the hematology domain. This case study highlights how timely, in-depth competitive intelligence empowered a Europe-based client to refine strategies, strengthen launch preparedness, and maintain a leadership position in the face of intense competition.
The rapidly evolving field of hematological malignancies, including Acute Myeloid Leukemia (AML), Multiple Myeloma, and…
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Cholangiocarcinoma
Cholangiocarcinoma Market to Reach USD 2.87 Billion by 2034
The global cholangiocarcinoma market is positioned for steady growth, driven by increasing awareness, improved diagnostic capabilities, and the expanding approval of targeted drugs. Between 2024 and 2034, a combination of innovative drug pipelines, biomarker-based diagnostics, and supportive policy frameworks is expected to transform patient outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70843
Market Overview
• Market Size (2024): USD 1.32 billion
• Forecasted Market Size (2034): USD 2.87 billion
• CAGR (2024-2034): ~8.1%
• Key Drivers: Genomic…
Cholangiocarcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2024" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma pipeline…
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032…
Global Cholangiocarcinoma Market
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Overview by Advance Technology, Future Outlook 2032
The global cholangiocarcinoma market size was valued at USD 185 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 12.5% in the forecasted period. The high expenditure on the healthcare sector by the management and the customers boosts the market growth. Increasing infection like liver fluke will boost the demand for the market, growing the treatment of bile duct cancer impacting…
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM"
The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma…
